Gene expression profiles in clinically T1-2N0 ER+HER2- breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed.
Lori M van RoozendaalMarissa L G VaneE ColierLuc J A StrobbeM de BoerGabe S SonkeMarissa C Van MaarenMarjolein L SmidtPublished in: Breast cancer research and treatment (2023)
If no SLNB is performed, clinical risk status according to the guideline of 2020 and PREDICT predicts a very low risk for systemic undertreatment. The number of GEPs needed to identify one patient at risk for undertreatment does not justify its standard use.
Keyphrases
- sentinel lymph node
- gene expression
- neoadjuvant chemotherapy
- lymph node
- early stage
- dna methylation
- case report
- ultrasound guided
- locally advanced
- fine needle aspiration
- estrogen receptor
- breast cancer cells
- stem cells
- breast cancer risk
- radiation therapy
- mesenchymal stem cells
- early breast cancer
- bone marrow
- drug induced